CRANNMED LIMITED

CrannMed Limited is a pioneering medical‑technology company dedicated to improving patient outcomes through resorbable embolisation. Founded in 2018, the firm unites world‑leading clinicians, material scientists and delivery‑system engineers to develop microsphere‑based therapies that safely block pathological blood vessels and then dissolve, restoring normal circulation. Their flagship product, SakuraBead, is a precisely calibrated, organic microsphere designed for Genicular Artery Embolisation (GAE) in knee osteoarthritis. By targeting the small vessels that fuel chronic inflammation, SakuraBead reduces swelling, alleviates pain and interrupts the degenerative cycle that often leads to total knee replacement.

Beyond the core technology, CrannMed runs the SURE clinical study for a novel knee‑osteoarthritis treatment and publishes results from its pilot trials, demonstrating the long‑term benefits of resorbable embolisation for patients worldwide. With a focus on safety, re‑intervention flexibility and patient‑centred outcomes, CrannMed offers a new therapeutic alternative for the millions suffering from symptomatic knee osteoarthritis.